Akums Drugs Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹11.8K Cr

The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force. CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.

From Akums Drugs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Price

₹758

Market Cap

₹11.8K Cr

P/E Ratio

38.7

How does Akums Drugs rank in Pharmaceuticals & Biotechnology?

Compare Akums Drugs against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 2

View Pharmaceuticals & Biotechnology leaderboard →

Akums Drugs — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 3

→The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force.
→CDMO segment showed healthy volume growth of over 18% year-on-year; Q2 volume growth also looks strong at high teens, with positive momentum expected to continue.
→Overall volume growth in the industry is expected to sustain, with the company positioned to outperform market growth.
→New manufacturing capacities (e.g., in oral tablets and a new facility in Baddi) coming online by year-end are expected to support volume growth.
→International branded formulations and Zambia business are forecasted to contribute revenue growth, with Zambia expected to recognize revenues in H2 FY27 and European business operations kicking in next year.
→The API business aims to become monthly EBITDA positive by Feb-Mar FY27, turning profitable next year, with single-digit growth expected by FY28.

📈 Profitability & Margins

Rank 2

→CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.
→API business targets to achieve monthly EBITDA breakeven by Feb-Mar FY27; expects profitability and positive contribution in FY28.
→Domestic branded formulation (Akumentis) anticipates double-digit volume growth for FY27 due to increased MR field force and capacity expansion.
→International branded formulations expect return to growth in coming quarters after a muted Q1.
→EBITDA margins expected to remain strong at around 14-15%; current margins incline towards the higher side.
→Overall company margins improved by over 230 basis points YoY; Q1 FY27 PAT increased 56.1% YoY.
→New capacities in oral tablets to go live by year-end, enabling sustained volume growth.
→Zambia and European business expected to contribute significant revenues and uplift margins in H2 FY27 and FY28.
→Strategic investments and acquisitions aim to drive future profitable growth and margin expansion.

See what Akums Drugs said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
→The capex for this new facility is still under discussion and will be updated once finalized.
→The company has INR1,600 crores of cash on the balance sheet, mostly parked in fixed deposits with nationalized banks, with no debt.
→Akums is open to acquisitions that are value-accretive and strategically rational to the group, indicating potential future inorganic investments.
→Management emphasizes cautious capital allocation for acquisitions, focusing on business synergies and profitability enhancement.
→Recent acquisition of Oriflame India's manufacturing business expanded capacities in skincare cosmetics and wellness products, aligning with the strategy of tapping niche formulations.

💰 Fundraising & Capital Structure

No information

→No current or immediate plans for fundraising through debt or equity were mentioned.
→The company has a strong balance sheet with net worth over INR 3,400 crores and zero debt.
→They have a cash surplus of approximately INR 1,600 crores, mostly in fixed deposits with nationalized banks.
→The management indicated an appetite for acquisitions if value-accretive opportunities arise, utilizing available cash reserves.
→Any future capital allocation decisions, including acquisitions, will be communicated once finalized.
→Overall, the company is financially robust and prefers using internal accruals and cash reserves for growth rather than raising fresh capital at this time.

See what Akums Drugs said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

Yes

The transcript does not explicitly provide specific details about the current or expected order book or pending orders for Akums Drugs & Pharmaceuticals Limited. However, relevant insights include: - Advanced stages of agreement for supplying over 100 products to the Zambian government, expected to generate around $25 million revenue in H2 FY27. - European business expected to kickstart in FY28, contributing positively to revenue and margins. - Sustained volume growth in CDMO and international markets with new capacity additions planned. - No subcontracting; focus on utilizing existing and new facilities (one new oral manufacturing facility planned by end of FY27). - Order volumes and capacity utilization are improving with a peak utilization target of around 55-60%. No exact quantitative order book or pending order figures were disclosed in the transcript.

Key Metrics

2 of 5 growth signals positive in the Q1 FY27 call.

Revenue

Rank 3

Margin

Rank 2

Capex

Yes

Fundraise

No information

Order Book

Yes

How does Akums Drugs rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

What AKUMS's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Ind-Swift Laboratories Ltd (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
HIKAL (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Akums Drugs Q1 FY27 results?

What is Akums Drugs share price analysis?

Akums Drugs currently shows a below-average growth signal. The stock trades at a P/E of 38.7 with a market cap of ₹11,805 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs planning capital expenditure?

Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.

Keep Akums Drugs on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.